Tuesday, August 22, 2017
Company News: Page (1) of 1 - 08/12/17 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Dr. Reddy's (RDY) Alert: J&W Investigates Dr. Reddy's Laboratories Ltd.; Has Your Dr. Reddy's Investment Declined in Value?
(August 12, 2017)

SAN DIEGO, Aug. 12, 2017 /PRNewswire/ -- Shareholder rights law firm Johnson & Weaver, LLP is investigating potential violations of the federal securities laws by Dr. Reddy's Laboratories Ltd. (NYSE: RDY) and certain of its officers. Dr. Reddy's operates as an integrated pharmaceutical company worldwide.

On November 6, 2015, Dr. Reddy's reported that the Company received a "warning letter" from U.S. regulators over inadequate quality controls at three manufacturing plants producing drugs for cancer and other diseases. The next trading day, on November 9, the Company held an investor conference call to discuss the warning letter.  On the call, it was further revealed that it was not just the three facilities singled out in the warning letter that was experiencing problems.  In fact, the FDA required Dr. Reddy's to implement changes for every manufacturing site the Company operated.  Specifically, Dr. Reddy's disclosed to investors that the FDA found deficiencies in its documentation practices and control, laboratory testing practices, adequacy of standard operating procedures, and incident investigation practices.

Then, on August 10, 2017, Dr. Reddy's disclosed that the Regulatory of Germany (Regierung von Oberbayern), following a recent inspection of the plant, did not renew the good manufacturing practices compliance certificate of a manufacturing unit of Dr. Reddy's German subsidiary Betapharm Arzneimittel, located in Hyderabad, India. Following these disclosures, the price of Dr. Reddy's plummeted.

If you have information that could assist in this investigation, or if you are a Dr. Reddy's shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker ([email protected]) by email or by phone at 619-814-4471. If emailing, please include a phone number.

About Johnson & Weaver, LLP:

Johnson & Weaver, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonandweaver.com. Attorney advertising. Past results do not guarantee future outcomes.

Johnson & Weaver, LLP
Jim Baker, 619-814-4471
[email protected]

View original content:http://www.prnewswire.com/news-releases/dr-reddys-rdy-alert-jw-investigates-dr-reddys-laboratories-ltd-has-your-dr-reddys-investment-declined-in-value-300503513.html

SOURCE Johnson & Weaver, LLP

Copyright 2014 PR Newswire. All Rights Reserved

Page: 1

Related Keywords:USA, Surgery, Medication, Science, Medical, Cancer, Email, Other,
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter

  • Medical Sector Contract Electronic Manufacturing Market shows lucrative growth CAGR of 8.8 % by 2022
  • Informa Names Sixth Annual SupplySide CPG Editors Choice Award Finalists
  • Growth Opportunities in the Global Sleep Apnea Devices Market 2017: Segmented by Product type, Treatment Devices, End-User and Geography - Growth, Trends, and Forecasts (2017 - 2024)
  • BIOTRONIK US Launches Smallest MR Conditional Quadripolar Cardiac Resynchronization Therapy Pacemaker
  • Global Contrast Injector Market Will Reach USD 889.3 Million by 2022: Zion Market Research

  • Gaucher Disease Market Is Anticipated To Witness Growth Owing To Increasing R&D Activities And Special Facility For Orphan Drugs Till 2021 | Million Insights
  • CytRx Corporation Files Preliminary Proxy Statement for Upcoming Special Meeting
  • Astronauts Showcase Space Art Created with Childhood Cancer Patients
  • Three Grant Funding Opportunities for Brain Tumor Research Funding Open Today
  • argenx to host conference call & webcast to report second quarter business update and half year 2017 financial results on August 24, 2017

    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines